in vitro dynamic model

Objective. To study pharmacodynamics of meropenem alone and in combination with avibactam in an in vitro dynamic model; to evaluate effectiveness of meropenem against K. pneumoniae strains producing and not producing carbapenemases; to study impact of bacterial inoculum on meropenem activity and its effects. Materials and Methods. K. pneumoniae producing KPC and OXA-48 carbapenemases and non-producing strains were exposed to meropenem or its combination with avibactam (carbapenemase-producing strains only) in a modified in vitro hollow-fiber infection model (pneumoniae) simulating human pharmacokinetics of drugs administrated thrice daily for 5 days.

To compare the pharmacodynamics of daptomycin (DAP) and vancomycin (VAN) as well as killing kinetics of S. aureus with different MICs were studied at widely ranged AUC/MIC ratios. Two clinical isolates, S. aureus 866 (MICDAP 0.35 µ/ml and MICVAN 0.70 …

To study the hypothesis of the mutant selection window (MSW) in a pharmacodynamic context, the susceptibility of a clinical isolate of methicillin-resistant Stap. hylococcus aureus exposed to moxifloxacin (MOX), levofloxacin (LEV) and ciprofloxacin …